Taking the next step in PARP-inhibitor clinical trials in older women with ovarian cancer – Staging the aging

• Older patients are still underrepresented in randomized controlled clinical trials. • Older patients receiving PARP-inhibitors tend to achieve shorter PFS, even those considered fit. • Older patients experience more side effects, than their younger counterparts. • Prospective “real-world” data is...

Descripción completa

Detalles Bibliográficos
Autores principales: Liposits, G., Lichtman, S.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846923/
https://www.ncbi.nlm.nih.gov/pubmed/33553556
http://dx.doi.org/10.1016/j.gore.2021.100710
_version_ 1783644834452471808
author Liposits, G.
Lichtman, S.M.
author_facet Liposits, G.
Lichtman, S.M.
author_sort Liposits, G.
collection PubMed
description • Older patients are still underrepresented in randomized controlled clinical trials. • Older patients receiving PARP-inhibitors tend to achieve shorter PFS, even those considered fit. • Older patients experience more side effects, than their younger counterparts. • Prospective “real-world” data is needed in unselected older women with ovarian cancer receiving PARP-inhibitors.
format Online
Article
Text
id pubmed-7846923
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78469232021-02-04 Taking the next step in PARP-inhibitor clinical trials in older women with ovarian cancer – Staging the aging Liposits, G. Lichtman, S.M. Gynecol Oncol Rep Correspondence • Older patients are still underrepresented in randomized controlled clinical trials. • Older patients receiving PARP-inhibitors tend to achieve shorter PFS, even those considered fit. • Older patients experience more side effects, than their younger counterparts. • Prospective “real-world” data is needed in unselected older women with ovarian cancer receiving PARP-inhibitors. Elsevier 2021-01-24 /pmc/articles/PMC7846923/ /pubmed/33553556 http://dx.doi.org/10.1016/j.gore.2021.100710 Text en © 2021 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Correspondence
Liposits, G.
Lichtman, S.M.
Taking the next step in PARP-inhibitor clinical trials in older women with ovarian cancer – Staging the aging
title Taking the next step in PARP-inhibitor clinical trials in older women with ovarian cancer – Staging the aging
title_full Taking the next step in PARP-inhibitor clinical trials in older women with ovarian cancer – Staging the aging
title_fullStr Taking the next step in PARP-inhibitor clinical trials in older women with ovarian cancer – Staging the aging
title_full_unstemmed Taking the next step in PARP-inhibitor clinical trials in older women with ovarian cancer – Staging the aging
title_short Taking the next step in PARP-inhibitor clinical trials in older women with ovarian cancer – Staging the aging
title_sort taking the next step in parp-inhibitor clinical trials in older women with ovarian cancer – staging the aging
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846923/
https://www.ncbi.nlm.nih.gov/pubmed/33553556
http://dx.doi.org/10.1016/j.gore.2021.100710
work_keys_str_mv AT lipositsg takingthenextstepinparpinhibitorclinicaltrialsinolderwomenwithovariancancerstagingtheaging
AT lichtmansm takingthenextstepinparpinhibitorclinicaltrialsinolderwomenwithovariancancerstagingtheaging

Ejemplares similares